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Abstract
Accumulation and aggregation of the microtubule-associated protein tau are a pathological hallmark of
neurodegenerative disorders such as Alzheimer’s disease (AD). In AD, tau becomes abnormally phosphorylated and
forms inclusions throughout the brain, starting in the entorhinal cortex and progressively affecting additional brain
regions as the disease progresses. Formation of these inclusions is thought to lead to synapse loss and cell death.
Tau is also found in the cerebrospinal fluid (CSF), and elevated levels are a biomarker for AD. Until recently, it was
thought that the presence of tau in the CSF was due to the passive release of aggregated tau from dead or dying
tangle-bearing neurons. However, accumulating evidence from different AD model systems suggests that tau is
actively secreted and transferred between synaptically connected neurons. Transgenic mouse lines with localized
expression of aggregating human tau in the entorhinal cortex have demonstrated that, as these animals age, tau
becomes mislocalized from axons to cell bodies and dendrites and that human tau-positive aggregates form first in
the entorhinal cortex and later in downstream projection targets. Numerous in vitro and in vivo studies have
provided insight into the mechanisms by which tau may be released and internalized by neurons and have started
to provide insight into how tau pathology may spread in AD. In this review, we discuss the evidence for regulated
tau release and its specific uptake by neurons. Furthermore, we identify possible therapeutic targets for preventing
the propagation of tau pathology, as inhibition of tau transfer may restrict development of tau tangles in a small
subset of neurons affected in early stages of AD and therefore prevent widespread neuron loss and cognitive
dysfunction associated with later stages of the disease.
Tau pathology in neurodegenerative disease
Tau is a soluble, unfolded microtubule-associated protein
that regulates cytoskeletal dynamics of neurons in the cen-
tral nervous system [1]. Under pathological conditions,
tau becomes abnormally phosphorylated and aggregates
into filamentous brain inclusions referred to as neurofib-
rillary tangles (NFTs) [2]. Although tau composition and
structure of NFTs are well characterized, the process of
tangle formation is not well understood. The presence of
tau inclusions of various morphologies is characteristic
of a number of neurodegenerative diseases called tauo-
pathies, including Alzheimer’s disease (AD), Pick’sd i s e a s e ,
and frontotemporal dementia [3]. AD is characterized by
neuronal and synapse loss and histopathologically by two
hallmark lesions: amyloid-β-containing plaques and NFTs.
In AD, NFTs accumulate in a hierarchical pattern affecting
selectively vulnerable brain regions that are essential for
learning and memory [4]. Progression of NFT pathology
throughout the brain correlates well with decline in cogni-
tive function [5]. The entorhinal cortex (EC) is the first
cortical region affected by NFTs, followed by the hippo-
campus, and ultimately the neocortex [6]. Progression of
NFTs appears to propagate across limbic and association
cortices, creating a predictable pattern that permits the
neuropathological diagnosis of different AD stages [6,7].
The loss of NFT-affected neurons results in disconnection
and deafferentation of critical neural circuits [8] and thus
is likely to contribute to the defects in memory and
higher-order cognitive functions in AD.
The spread of protein aggregates during disease progres-
sion is a common theme in many neurodegenerative dis-
orders, including α-synuclein in Parkinson’sd i s e a s e[ 9 ]a n d
superoxide dismutase-1 in amyotrophic lateral sclerosis
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spread of these aggregates, including tau, is unknown. Re-
cent studies propose that AD and other neurodegenerative
disorders, though not demonstrated to be infectious, may
involve transfer of misfolded proteins between cells, similar
to what is observed in prion disease [11,12]. These disor-
ders are said to be ‘prion-like’, since they lack the infectious
properties that characterize true prion diseases (for review,
see [13]). However, precisely which cellular mechanisms
underlie the spread of protein aggregates, including the
propagation of pathological tau in AD, remain unclear.
Models of tau propagation
Substantial progress has recently been made in under-
standing the pathogenic mechanisms of tau spreading
between neurons and across brain regions. Three inde-
pendent research groups modeled the process of tau
spreading by using transgenic mouse lines with localized
expression of aggregating human tau. To generate these
mouse lines, neuropsin promoter-driven tTa mice that
express this transcriptional activator mainly in the med-
ial EC [14] were crossed with a responder mouse line
that expresses human tau carrying the P301L mutation
[15]. The resulting mice express transgenic mutant tau
almost exclusively in the medial EC [16-18]. As these an-
imals age, the distribution of tau in the brain alters. Tau
becomes mislocalized from axons to cell bodies and den-
drites in the EC, and human tau-positive NFT-like ag-
gregates form first in the EC and later in downstream
projection targets of EC neurons, suggesting trans-
synaptic propagation of tau [16-18].
Until recently, the spread of tau pathology in AD was
attributed to the passive release of aggregated tau from
dead or dying tangle-bearing neurons. However, a num-
ber of recent studies demonstrated active secretion and
interneuronal transfer of tau in different AD model sys-
tems [17-25], suggesting that neuronal tau release is a
regulated process that could facilitate the trans-neuronal
spread of tau misfolding. Therefore, understanding how
inter-neuronal transfer of tau occurs may provide poten-
tial therapeutic targets to interrupt the proliferation of
tau pathology early in disease. In this review, we discuss
the cellular mechanisms of tau propagation and poten-
tial therapeutic approaches.
Tau is secreted in the absence of
neurodegeneration
Although tau is primarily an axonal cytoplasmic protein, it
has also been shown to be present at both the pre- and
post-synapse in human brain [26] as well as the post-
synaptic compartment of mouse brain [27]. Interestingly,
tau directly interacts with synaptic proteins, such as the
NMDA receptor [27,28], suggesting a role for tau in regu-
lating intracellular signaling pathways [29]. Extracellularly,
tau is also found in brain fluids such as cerebrospinal fluid
(CSF) [30] and interstitial fluid (ISF) [31]. Tau is present in
the CSF of both healthy and AD individuals, whereby
changes in tau concentrations and phosphorylation state
are observed in AD and might be useful as a disease bio-
marker (for review, see [32]). However, the presence of tau
in the CSF of healthy individuals, without AD-related
widespread neuron loss, is not well understood. Tau is
detected in the ISF of awake wild-type mice by using
in vivo microdialysis, further suggesting that it is also re-
leased by neurons in the absence of neurodegeneration
[31]. There is accumulating evidence that tau secretion is
an active neuronal process, independent of cell death
[22,23], and since tau is present in both axons and den-
drites, it is possible that either region may be involved its
release. However, tau can also be released from, and taken
up by, cultured non-neuronal cells, suggesting that synap-
tic mechanisms may not be uniquely involved in this
process. From cell lines stably expressing tau, it has been
estimated that 0.1% to 0.3% of total cellular tau is secreted
[33,34]; however, estimates for neuronal tau secretion
in vivo have yet to be determined.
Mechanisms of neuronal tau release
How do neurons secrete tau? This question has been the
subject of several recent studies but remains controver-
sial. Specifically, whether tau is released in a free soluble
form or packaged into small membrane vesicles such as
exosomes is unclear. Since exosomal membrane is de-
rived from the plasma membrane [35] and tau is associ-
ated with the plasma membrane [36,37], it is possible
that tau packaged in exosomes is actively secreted in this
manner. Consistent with this hypothesis, tau was
detected in exosomes isolated from CSF of both healthy,
age-matched controls and AD patients [22]. Earlier stud-
ies of tau secretion performed in human tau overex-
pressing non-neuronal cell lines – COS-7 and human
embryonic kidney (HEK) – showed that tau release in
microvesicles, in the absence of cell death, is an actively
regulated process [38]. Furthermore, neuroblastoma
M1C cells that inducibly express wild-type human tau
secreted both free soluble and exosomal tau [22]. Hu-
man tau overexpression in giant neurons of the lamprey
caused the release of tau contained within various types
of vesicles [20] and subsequent dendritic degeneration.
These results suggest that non-microtubule-associated
intracellular tau may be packaged and secreted within
neuron-derived vesicles. However, whether exosomal tau
release is a regulated neuronal process in vivo or results
from overexpression and missorting of tau in these cell
models remains unclear.
However, a number of recent studies report that tau
may be released from cells by a mechanism that does not
involve membrane vesicles. Analysis of culture medium
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than transiently overexpressing tau, revealed soluble extra-
cellular tau but no detectable tau in the exosome fraction
[33]. Exosomes isolated from SH-SY5Y neuroblastoma
cells, infected with a lentivirus to express human GFP-
tagged tau, also did not contain tau [39]. Furthermore,
increased neuronal activity in cortical neuron cultures
stimulates the release of non-exosomal endogenous tau
[23]. The absence of tau in neuronal exosomes is sup-
ported by proteomic analysis of exosomes derived from
cortical neurons [40] and from human neural stem cells
[41]. These studies showed that neuron-derived exosomes
contain cytoskeletal proteins, including β-tubulin, but do
not possess detectable amounts of tau. Taken together,
these studies suggest that free soluble, rather than mem-
brane vesicle-associated, tau is released in the brain. How-
ever, under which conditions neurons release tau and
whether multiple secretion mechanisms are involved need
further investigation.
The discrepancy between the reported exosomal versus
soluble secreted tau may result from the use of different
model systems: studies showing exosomal or vesicular se-
cretion of tau all involve overexpression of the protein,
whereas physiological tau expression levels seem to favor
the release of soluble tau. Depending on the cell type, high
levels of intracellular tau may lead to toxicity; indeed,
exosomal localization of tau was observed in degenerating
cells [20]. Furthermore, in a cell culture model, in which
tau is inducibly expressed, tau release was detectable in the
absence of cytotoxicity and was not associated with vesicles
[21,33]. In cortical neurons and neuroblastoma cells, the
level of tau secretion appears to be low, suggesting a consti-
tutive release of endogenous tau. The amount of tau se-
creted is greatly increased after stimulation of neuronal
activity and seems to depend on changes in intracellular
calcium [23,34]. Such activity-regulated tau release opens a
new view on the progression of tau pathology in AD. There
is evidence that disease-relevant tau mutations may have
an impact on tau release as well: in vitro expression of tau
harboring the P301S mutation in human neuroblastoma
cells decreases tau release [34], whereas mice expressing
human P301S tau show higher tau levels in ISF compared
with wild-type mice [31]. Therefore, further research using
animal models of the disease is needed to reveal whether
tau release is dynamic and regulated by neuronal activity
in vivo and whether it may be altered in neurodegeneration.
Importantly, understanding the mechanism of tau secretion
in the brain could open the way to new plausible drug tar-
gets for the treatment of AD, as reduction of tau secretion
m a yp r e v e n tt h es p r e a do ft a n g l ep a t h o l o g y .
Characterization of extracellular tau
Since tau has been demonstrated to propagate between
neurons, determining which species of tau are involved
in its intercellular transfer is of great interest. The phos-
phorylation state and length of extracellular tau have
been reported in numerous studies, but obtaining a glo-
bal picture is difficult since different epitopes were
analyzed in various model systems. Analysis of tau in
human CSF found that levels of tau phosphorylated on
T181 are increased in patients with AD compared with
healthy controls [42]. Phosphorylation of this epitope
was also observed in extracellular tau in vitro, released
from HEK cells [33] and neuroblastoma M1C cells [22]
both inducibly expressing wild-type human tau, and in
endogenous tau from SH-SY5Y neuroblastoma cells [43]
and mouse cortical neurons [34]. However, tau secreted
from cultured cortical neurons was reported to be de-
phosphorylated at the Tau1 (S199/202) and PHF1 (S396/
404) epitopes [23]; tau released from transfected HeLa
cells was also shown to be dephosphorylated at the AT8
(S202/T205) and PHF1 epitopes [21]. The phosphoryl-
ation status of tau as it is released may be difficult to
ascertain, however, as extracellular phosphatases may
dephosphorylate tau once it is outside the cell [44].
Examination of tau released from human neuroblastoma
SH-SY5Y cells revealed that when activity of tissue-
nonspecific alkaline phosphatase was blocked, levels of
extracellular tau phosphorylated at the AT8 and PHF1
epitopes were significantly increased [44]. These results
suggest that tau phosphorylation may be altered extra-
cellularly, and this is of particular interest as changes in
extracellular tau phosphorylation may underlie tau
propagation in AD. Truncation of extracellular tau is the
subject of conflicting reports. HeLa cells overexpressing
GFP-tagged human tau have been demonstrated to re-
lease tau that is cleaved at D421, a caspase-3 cleavage
site [21]. However, additional studies report intact, full-
length extracellular tau in vitro [23,34] and in vivo [31].
Although it is known that neurons readily take up tau
aggregates [45,46] (as will be discussed in the next sec-
tion of this review), the extracellular species of tau that
propagates between neurons in vivo is not known. Vari-
ous forms of tau, including monomers, oligomers, or fi-
brils, could be involved in the spread of tau aggregates.
Furthermore, soluble tau monomers or oligomers may
be released from cells before tangle formation. A recent
study suggests that various types of tau may be trans-
ferred between cells, since inoculation of tau-enriched
extracts of human brain from individuals with various
tauopathies, including AD, frontotemporal dementia,
and corticobasoganglionic degeneration, propagated to
neurons in a mouse expressing wild-type human tau and
even to mice that express only endogenous mouse tau
[47]. To date, reports analyzing tau release in cell culture
systems [34] or in a mouse model of tauopathy [31] sug-
gest that extracellular tau released from healthy cells is
largely monomeric. However, extracellular tau has not
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bral inoculation aggregated tau is used to initiate propa-
gation of tangles [46-48]. In these models, released tau
may have abnormal phosphorylation or be oligomeric;
however, further studies are required to characterize the
species of tau that propagates under these conditions.
Neurons internalize extracellular tau
Knowledge about neuronal uptake of tau, which may fa-
cilitate tau spreading in AD and other tauopathies, is
still very limited. As discussed above, tau can be released
by neurons into extracellular space and therefore may be
available for uptake by neighboring cells. Several recent
studies have explored the nature of the tau that is taken
up by neighboring neurons and aimed to uncover the
mechanism by which this process occurs.
Propagation of aggregated tau has been recently ex-
plored in vivo by brain inoculation of tau aggregates and
monitoring their uptake and propagation in mouse cortex.
Injection of tau filaments from transgenic mice expressing
human mutant P301S tau into hippocampi of young mice
expressing wild-type human tau caused filamentous tau
inclusions of the wild-type tau and the spreading of path-
ology from the site of injection to neighboring brain
regions [24]. In a follow-up study, brain extracts from
sporadic human tauopathy cases were injected intracere-
brally into wild-type mice. Injected mice displayed highly
phosphorylated tau inclusions in several brain regions, in-
dicating that, in this model, the presence of mouse tau
was sufficient for propagation of pathology [47]. Interest-
ingly, aggregates were found in both astrocytes and neu-
rons [47], suggesting that multiple cell types may be able
to internalize tau and participate in propagation of tau
pathology.
However, it is not clear which component of the inoc-
ulated brain material – the tau aggregates or a soluble
tau species – is responsible for transmitting tau path-
ology. Several studies have directly tested the uptake of
various forms of tau to determine whether cells prefer-
entially internalize specific types of tau. For example, in
cultured neurons treated with either low-molecular-
weight aggregates, short fibrils, or long fibrils composed
of recombinant full-length tau, only aggregates and short
fibrils were internalized [49]. Cells also take up paired
helical filaments (PHFs) of tau isolated from AD brain;
both HEK and SH-SY5Y neuroblastoma cells internal-
ized exogenously applied PHFs by endocytosis [39]. Fur-
thermore, in C17.2 neural stem cells treated with a
monomeric or oligomeric recombinant tau microtubule-
binding domain construct (amino acids 243 to 375), a
majority of cells took up oligomeric tau, although a
small percentage internalized monomeric tau [45]. Inter-
estingly, HEK cells overexpressing this tau construct
formed aggregates which were released and internalized
by other HEK cells [50], providing direct evidence that
microtubule-binding domain fragments of tau aggregates
can be transferred between cells in vitro.
Recent in vivo studies have explored whether certain
forms of tau are preferentially propagated. To determine
whether different types of tau aggregates could be taken
up by neurons, synthetic preformed fibrils of recombin-
ant human full-length tau or a truncated form of tau,
containing only the microtubule-binding domain, were
injected intracerebrally into young mice expressing hu-
man mutant P301S tau [46]. Both forms of fibrils were
internalized by cells, likely by endocytosis [51], and over
time human tau-positive inclusions were found through-
out the brain, indicating that both full-length or trun-
cated tau may be propagated in vivo [46]. However,
another study, using tau isolated from AD brain, sug-
gests that cells might discriminate in the types of tau in-
ternalized in vivo. When oligomeric or PHF tau was
injected in the hippocampus of young, wild-type mice,
only the tau oligomers, not brain-derived PHF, induced
tau pathology 11 months post-injection [48]. Interest-
ingly, both oligomeric and PHF tau were internalized by
cells near the injection site, but only oligomeric tau was
propagated to other brain regions, suggesting that PHF
tau may not be transported and released by neurons
[48]. This study supports a critical role of mouse tau in
propagation of tau pathology in mouse models since, in
tau knockout mice, no propagation of oligomeric tau
was observed. Furthermore, the aggregates found in
brain areas distal to the injection site were composed of
mouse and not human tau, indicating that the tau
propagation was not simply transfer of the injected ma-
terial [48], in agreement with recently reported findings
using a different mouse model [47].
The exact mechanism by which cells internalize tau re-
mains unknown; it may be dependent upon the tau spe-
cies (for example, monomers, small soluble oligomers,
or aggregates). Further work is required to better under-
stand whether the spread of tau inclusions is due to a
prion-like mechanism, in which misfolded tau induces
other tau molecules to become similarly misfolded [52].
In this manner, misfolded or aggregated tau might act as
a template, altering the conformation of tau in each
neuron that internalizes it. However, in the case of tau
aggregates, it remains unclear whether misfolded tau can
alter conformation of other tau molecules directly or
whether these aggregates interact with other cellular fac-
tors, like kinases, to alter tau in a way that would induce
changes in conformation [53]. Internalization of tau may
be different for isoforms that vary in number of micro-
tubule repeat domains and N-terminal inserts or in
post-translational modifications such as phosphorylation
and truncation state. The studies discussed above indi-
cate that soluble oligomeric tau is taken up and released
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facilitates the transmission of tau misfolding between
cells, suggesting that therapies such as small-molecule
tau aggregation inhibitors (reviewed in [54]), which
might reduce accumulation of extracellular tau oligo-
mers, might also slow transmission of tau pathology.
Therapeutic intervention and tau propagation
Accumulating evidence therefore suggests that inhibiting
the intercellular transfer of tau may slow or halt the pro-
gression of tau pathology in AD. Furthermore, as tau
pathology is associated with synapse loss [55] and subse-
quent cell death [56], prevention of its spread may also
impact disease-related cognitive decline. Therapeutic
strategies for preventing or reducing the interneuronal
transfer of tau may take several approaches: blocking tau
release, reducing accumulation or oligomerization of
extracellular tau, or preventing tau uptake (Figure 1).
Targeting tau release may enable reduction of extracellu-
lar tau levels, thereby reducing its availability for uptake
by neighboring neurons. Since neurons release tau in vivo
[31], possibly in an activity-dependent manner [23], fur-
ther research is needed to determine the precise mechan-
ism, which would be crucial for identifying targets for
therapeutic intervention. Interestingly, the presence of
extracellular tau in the absence of neurodegeneration, as
described above, suggests that perhaps tau may have a yet
unknown function outside the cell (for example, by par-
ticipating in cell-cell signaling). Indeed, exogenously ap-
plied recombinant tau has been shown to bind and
activate muscarinic acetylcholine receptors in cultured
hippocampal neurons with an affinity higher than that of
acetylcholine [57,58]. Additional work is needed to deter-
mine whether tau can stimulate these receptors in vivo,a s
these studies suggest that, although inhibition of tau re-
lease may halt inter-neuronal transfer of tau pathology,
care must be taken to ensure that normal functions of
extracellular tau are preserved. Furthermore, although re-
cent studies suggest that neurons may preferentially
internalize and propagate oligomeric tau in vivo [47,48],
Figure 1 Potential therapeutic targets to slow or prevent the spread of tau pathology in the brain. The mechanisms by which toxic tau
species are transferred between cells are not known; further investigation is required to understand how tau is released into extracellular space
and internalized. It is also unclear which species of tau are involved at each stage; neurons may release monomeric or oligomeric tau, which may
include toxic forms of soluble tau. Released tau may also be misfolded, and may have modifications such as abnormal phosphorylation,
truncation or both. As these mechanisms are better understood, potential therapeutic targets that will prevent or slow the spread of pathological
tau may be uncovered. For example, the release and uptake of tau may be inhibited pharmacologically, and immunotherapy might lower
extracellular tau concentration. Furthermore, anti-aggregant drugs may prevent tau oligomerization, reducing levels of potentially toxic forms of
tau that are available to be internalized.
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additional research in order to identify which type (or
types) of tau may be internalized and how this process
may occur.
The spread of pathogenic tau may also be slowed or
prevented by treatments that reduce levels of extracellular
tau or that alter tau such that neurons are no longer able
to internalize it. For example, inhibition or reversion of
extracellular tau oligomerization might interfere with tau
pathology spreading [54]; however, care needs to be taken
with this strategy, as disruption of tau aggregates may re-
sult in formation of other soluble species of tau, which
may also be toxic [59]. Therefore, prevention of extracellu-
lar tau accumulation or removal of pathological tau
species may prove to be a more cautious method. Inte-
restingly, recent studies of passive immunization of a
tauopathy mouse model with antibodies directed against
tau significantly prevented the formation of NFTs [60] or
ameliorated existing tau pathology in older animals [61].
Active immunization, in which mice were inoculated with
tau peptides, also proved effective at preventing and im-
proving tau pathology in mice overexpressing human
P301L tau [62]. Although tau immunotherapy has been
successful in animal models, clinical trials will provide im-
portant information about whether anti-tau immunother-
apies may slow or reverse disease progression in AD [63].
These trials may demonstrate a reduction in tau inclusions
in AD brain, as found in an animal model of disease [61].
Furthermore, inhibition of tau transfer may restrict devel-
opment of tau tangles to brain regions affected in early
stages of AD and therefore prevent the cognitive dysfunc-
tion associated with later stages of the disease.
Conclusions
Propagation of tau pathology in the brain is a hallmark
of AD. However, only recently have the mechanisms
underlying the interneuronal transmission of tau been
explored. Further understanding of these processes will
be important for identification of novel therapeutic tar-
gets aimed at halting the spread of tau aggregation. Al-
though progress has been made in identifying the tau
species involved in propagation, further research is
needed both in vitro and in vivo in order to identify pre-
cisely which forms of tau are involved in transmission of
pathology. Identifying these pathological tau species is
particularly important therapeutically, since these trans-
missible forms of tau may represent a specific target for
immunotherapy. Crucially, it will be important to target
pathological tau to minimize interference with normal
tau function.
Numerous questions with regard to how tau pathology
might be propagated in disease remain. For example, fur-
ther research may provide insight into whether non-
neuronal cell types regulate intercellular tau transfer, since
glia are able to internalize tau aggregates in a mouse
model of tauopathy [47] and glial tangles are also found in
frontotemporal dementia [64]. Furthermore, although tau
pathology appears to propagate along neural networks
[17,18] and its release is regulated by synaptic activity [23],
whether propagation of pathology occurs at synapses re-
mains to be demonstrated [26]. Therefore, further identifi-
cation and characterization of mechanisms of tau release
and uptake will be critical for therapeutic interventions
that may prevent or slow neurodegeneration in AD.
Note: This article is part of a series on Tau-based therapeutic
strategies, edited by Leonard Petrucelli. Other articles in this
series can be found at http://alzres.com/series/tau_therapeutics.
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